Download PDF
Aktuelle Dermatologie 2020; 46(08/09): 389-393
DOI: 10.1055/a-1150-0796
Eine Klinik im Blickpunkt

Aquagener Pruritus als Warnzeichen eines inneren Tumorleidens – eine Fallvorstellung und Literaturübersicht

Aquagenic Pruritus as a Danger Sign for an Internal Neoplasm – A Case Report and Literature Review
P. Troitzsch
Klinik und Poliklinik für Dermatologie, Universitätsmedizin Rostock
,
R. Panzer
Klinik und Poliklinik für Dermatologie, Universitätsmedizin Rostock
,
S. Emmert
Klinik und Poliklinik für Dermatologie, Universitätsmedizin Rostock
,
A. Thiem
Klinik und Poliklinik für Dermatologie, Universitätsmedizin Rostock
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Aquagener Pruritus (AP), d. h. Jucken, Kribbeln, Brennen nach Wasserkontakt, ist ein häufiges Symptom bei Polycythaemia vera und anderen myeloproliferativen Neoplasien, kann aber auch unabhängig davon auftreten. Wie andere Formen des Pruritus schränkt AP die Lebensqualität der Betroffenen häufig ein und kann zu einem hohen Leidensdruck führen. Zur Pathogenese existieren unterschiedliche Erklärungsansätze, jedoch kein einheitliches Konzept. Passend dazu sprechen Patienten auch nur zum Teil auf vorhandene Therapien an, die überwiegend off label sind. In dieser Literaturübersicht zum AP werden beschriebene Pathomechanismen diskutiert und mögliche Therapieformen genannt. Ein verbessertes Verständnis von AP soll dazu beitragen, dieses Symptom zu erkennen und an mögliche zugrunde liegende Erkrankungen, insbesondere an ein inneres Tumorleiden, zu denken.

Abstract

Aquagenic pruritus, i. e. itching, tingling or burning after contact with water, is a frequent symptom of polycythaemia vera or other myeloproliferative neoplasia; however, it can also appear independently. As other forms of pruritus, it often limits daily life activities and can lead to high emotional distress. While different approaches regarding its pathogenesis exist, a comprehensive concept is not yet established. Accordingly, only some patients respond well to existing treatments, which are often off-label. This review of aquagenic pruritus discusses described pathogenic mechanisms and specifies possible therapeutic approaches. An improved knowledge about AP should help to recognize this symptom and consider potential underlying diseases, e. g. importantly an intern neoplasm.



Publication History

Article published online:
20 August 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Shelley W. Post-wetness (aquagenic) Pruritus. JAMA 1970; 212: 1385
    PubMedGoogle Scholar
  • 2 Handfield-Jones SE, Hills RJ, Ive FA. et al. Aquagenic pruritus associated with juvenile xanthogranuloma. Clin Exp Dermatol 1993; 18: 253-255
    CrossrefPubMedGoogle Scholar
  • 3 McGrath JA, Greaves MW. Aquagenic pruritus and the myelodysplastic syndrome. Br J Dermatol 1990; 123: 414-415
    CrossrefPubMedGoogle Scholar
  • 4 Khalifa N, Singer CR, Black AK. Aquagenic pruritus in a patient associated with myelodysplasia and T-cell non-Hodgkin's lymphoma. J Am Acad Dermatol 2002; 46: 144-145
    CrossrefPubMedGoogle Scholar
  • 5 Heitkemper T, Hofmann T, Phan NQ. et al. Aquagenic pruritus: associated diseases and clinical pruritus characteristics. J Dtsch Dermatol Ges 2010; 8: 797-804
    CrossrefPubMedGoogle Scholar
  • 6 Moreno Caballero B, Castro Barrio M, Blanco Andrés C. Aquagenic pruritus due to use of bupropion. Aten Primaria 2002; 30: 662-663
    PubMedGoogle Scholar
  • 7 Jiménez-Alonso J, Tercedor J, Jáimez L. et al. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus. Arthritis Rheum 1998; 41: 744-745
    CrossrefPubMedGoogle Scholar
  • 8 Mendlowicz MV, Lima JL, Fontenelle LF. Aquagenic pruritus induced by clomipramine. Gen Hosp Psychiatry 2013; 35: 577.e573-574
    CrossrefPubMedGoogle Scholar
  • 9 Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol 2001; 115: 619-621
    CrossrefPubMedGoogle Scholar
  • 10 Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol 2013; 88: 665-669
    CrossrefPubMedGoogle Scholar
  • 11 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-2405
    CrossrefPubMedGoogle Scholar
  • 12 Zoi K, Cross NC. Genomics of Myeloproliferative Neoplasms. J Clin Oncol 2017; 35: 947-954
    CrossrefPubMedGoogle Scholar
  • 13 Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest 2010; 40: 828-834
    CrossrefPubMedGoogle Scholar
  • 14 Le Gall-Ianotto C, Brenaut E, Gouillou M. et al. Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms. Br J Dermatol 2017; 176: 255-258
    CrossrefPubMedGoogle Scholar
  • 15 Jackson N, Burt D, Crocker J. et al. Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus. Br J Dermatol 1987; 116: 21-29
    CrossrefPubMedGoogle Scholar
  • 16 Abdel-Naser MB, Zaki MS, Mousa MH. et al. Cutaneous mononuclear cells and eosinophils are significantly increased after warm water challenge in pruritic areas of polycythemia vera. J Cutan Pathol 2007; 34: 924-929
    CrossrefPubMedGoogle Scholar
  • 17 Newton JA, Singh AK, Greaves MW. et al. Aquagenic pruritus associated with the idiopathic hypereosinophilic syndrome. Br J Dermatol 1990; 122: 103-106
    CrossrefPubMedGoogle Scholar
  • 18 Ishii T, Wang J, Zhang W. et al. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 2009; 113: 5942-5950
    CrossrefPubMedGoogle Scholar
  • 19 Wang J, Ishii T, Zhang W. et al. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. Leukemia 2009; 23: 1577-1586
    CrossrefPubMedGoogle Scholar
  • 20 Vannucchi AM, Antonioli E, Guglielmelli P. et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110: 840-846
    CrossrefPubMedGoogle Scholar
  • 21 Tefferi A, Lasho TL, Schwager SM. et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106: 631-635
    CrossrefPubMedGoogle Scholar
  • 22 Pieri L, Bogani C, Guglielmelli P. et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica 2009; 94: 1537-1545
    CrossrefPubMedGoogle Scholar
  • 23 Lengfelder E, Berger U, Hehlmann R. Interferon alpha in the treatment of polycythemia vera. Ann Hematol 2000; 79: 103-109
    CrossrefPubMedGoogle Scholar
  • 24 Verstovsek S. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad Med 2013; 125: 128-135
    CrossrefPubMedGoogle Scholar
  • 25 Verstovsek S, Passamonti F, Rambaldi A. et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014; 120: 513-520
    CrossrefPubMedGoogle Scholar
  • 26 Pardanani A, Tefferi A, Jamieson C. et al. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J 2015; 5: e335
    CrossrefPubMedGoogle Scholar
  • 27 Hermans MAW, Schrijver B, van Holten-Neelen CCPA. et al. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. Clin Exp Allergy 2018; 48: 1412-1420
    CrossrefPubMedGoogle Scholar
  • 28 Gilbert HS, Warner RR, Wasserman LR. A study of histamine in myeloproliferative disease. Blood 1966; 28: 795-806
    CrossrefPubMedGoogle Scholar
  • 29 Weick JK, Donovan PB, Najean Y. et al. The use of cimetidine for the treatment of pruritus in polycythemia vera. Arch Intern Med 1982; 142: 241-242
    CrossrefPubMedGoogle Scholar
  • 30 Reid CD. Pruritus preceding the development of polycythaemia vera. Lancet 1988; 2: 964
    CrossrefPubMedGoogle Scholar
  • 31 de Wolf JT, Hendriks DW, Egger RC. et al. Alpha-interferon for intractable pruritus in polycythaemia vera. Lancet 1991; 337: 241
    CrossrefPubMedGoogle Scholar
  • 32 Greaves MW, Black AK, Eady RA. et al. Aquagenic pruritus. Br Med J (Clin Res Ed) 1981; 282: 2008-2010
    CrossrefPubMedGoogle Scholar
  • 33 Bircher AJ, Meier-Ruge W. Aquagenic pruritus. Water-induced activation of acetylcholinesterase. Arch Dermatol 1988; 124: 84-89
    CrossrefPubMedGoogle Scholar
  • 34 Cao T, Yong AA, Tan KB. et al. Idiopathic aquagenic pruritus: pathogenesis and effective treatment with atenolol. Dermatol Ther 2015; 28: 118-121
    CrossrefPubMedGoogle Scholar
  • 35 Bircher AJ. Aquagenic pruritus: treatment with sodium bicarbonate and evidence for a seasonal form. J Am Acad Dermatol 1989; 21: 817
    CrossrefPubMedGoogle Scholar
  • 36 Bayoumi AH, Highet AS. Baking soda baths for aquagenic pruritus. Lancet 1986; 2: 464
    CrossrefPubMedGoogle Scholar
  • 37 Nosbaum A, Pecquet C, Bayrou O. et al. Treatment with propranolol of 6 patients with idiopathic aquagenic pruritus. J Allergy Clin Immunol 2011; 128: 1113
    CrossrefPubMedGoogle Scholar
  • 38 Haustein UF. Aquagenic pruritus. Dermatol Monatsschr 1984; 170: 654-656
    PubMedGoogle Scholar
  • 39 Murphy B, Duffin M, Tolland J. Aquagenic pruritus successfully treated with omalizumab. Clin Exp Dermatol 2018; 43: 858-859
    CrossrefPubMedGoogle Scholar
  • 40 Koh MJ, Chong WS. Aquagenic pruritus responding to combined ultraviolet A/narrowband ultraviolet B therapy. Photodermatol Photoimmunol Photomed 2009; 25: 169-170
    CrossrefPubMedGoogle Scholar
  • 41 Xifra A, Carrascosa JM, Ferrándiz C. Narrow-band ultraviolet B in aquagenic pruritus. Br J Dermatol 2005; 153: 1233-1234
    CrossrefPubMedGoogle Scholar
  • 42 Holme SA, Anstey AV. Aquagenic pruritus responding to intermittent photochemotherapy. Clin Exp Dermatol 2001; 26: 40-41
    CrossrefPubMedGoogle Scholar
  • 43 Menagé HD, Norris PG, Hawk JL. et al. The efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus. Br J Dermatol 1993; 129: 163-165
    CrossrefPubMedGoogle Scholar
  • 44 Ehrchen J, Ständer S. Pregabalin in the treatment of chronic pruritus. J Am Acad Dermatol 2008; 58: S36-37
    CrossrefPubMedGoogle Scholar
  • 45 Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005; 39: 2029-2037
    CrossrefPubMedGoogle Scholar
  • 46 Metze D, Reimann S, Beissert S. et al. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999; 41: 533-539
    PubMedGoogle Scholar
  • 47 Ingber S, Cohen PD. Successful treatment of refractory aquagenic pruritus with naltrexone. J Cutan Med Surg 2005; 9: 215-216
    CrossrefPubMedGoogle Scholar
  • 48 Phan NQ, Bernhard JD, Luger TA. et al. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol 2010; 63: 680-688
    CrossrefPubMedGoogle Scholar
  • 49 Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002; 99: 2627
    CrossrefPubMedGoogle Scholar
  • 50 Zylicz Z, Krajnik M, Sorge AA. et al. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003; 26: 1105-1112
    CrossrefPubMedGoogle Scholar
  • 51 Ständer S, Böckenholt B, Schürmeyer-Horst F. et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009; 89: 45-51
    CrossrefPubMedGoogle Scholar
  • 52 Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: End of the drought?. J Allergy Clin Immunol 2017; 140: 633-643
    CrossrefPubMedGoogle Scholar
  • 53 Wang F, Zhao YK, Luo ZY. et al. Aquagenic cutaneous disorders. J Dtsch Dermatol Ges 2017; 15: 602-608
    CrossrefPubMedGoogle Scholar